183 related articles for article (PubMed ID: 22871260)
1. Magnetic-activated cell sorting of TCR-engineered T cells, using tCD34 as a gene marker, but not peptide-MHC multimers, results in significant numbers of functional CD4+ and CD8+ T cells.
Govers C; Berrevoets C; Treffers-Westerlaken E; Broertjes M; Debets R
Hum Gene Ther Methods; 2012 Jun; 23(3):213-24. PubMed ID: 22871260
[TBL] [Abstract][Full Text] [Related]
2. gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells.
Walker EB; Haley D; Miller W; Floyd K; Wisner KP; Sanjuan N; Maecker H; Romero P; Hu HM; Alvord WG; Smith JW; Fox BA; Urba WJ
Clin Cancer Res; 2004 Jan; 10(2):668-80. PubMed ID: 14760090
[TBL] [Abstract][Full Text] [Related]
3. Comparison of peptide-major histocompatibility complex tetramers and dextramers for the identification of antigen-specific T cells.
Dolton G; Lissina A; Skowera A; Ladell K; Tungatt K; Jones E; Kronenberg-Versteeg D; Akpovwa H; Pentier JM; Holland CJ; Godkin AJ; Cole DK; Neller MA; Miles JJ; Price DA; Peakman M; Sewell AK
Clin Exp Immunol; 2014 Jul; 177(1):47-63. PubMed ID: 24673376
[TBL] [Abstract][Full Text] [Related]
4. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
Voelkl S; Moore TV; Rehli M; Nishimura MI; Mackensen A; Fischer K
Cancer Immunol Immunother; 2009 May; 58(5):709-18. PubMed ID: 18836718
[TBL] [Abstract][Full Text] [Related]
5. Clonal diversity of the T-cell population responding to a dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient.
Knutson KL; Disis ML
Hum Immunol; 2002 Jul; 63(7):547-57. PubMed ID: 12072190
[TBL] [Abstract][Full Text] [Related]
6. Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression.
Wehler TC; Karg M; Distler E; Konur A; Nonn M; Meyer RG; Huber C; Hartwig UF; Herr W
J Immunol Methods; 2008 Nov; 339(1):23-37. PubMed ID: 18760281
[TBL] [Abstract][Full Text] [Related]
7. RNA-transfection of γ/δ T cells with a chimeric antigen receptor or an α/β T-cell receptor: a safer alternative to genetically engineered α/β T cells for the immunotherapy of melanoma.
Harrer DC; Simon B; Fujii SI; Shimizu K; Uslu U; Schuler G; Gerer KF; Hoyer S; Dörrie J; Schaft N
BMC Cancer; 2017 Aug; 17(1):551. PubMed ID: 28818060
[TBL] [Abstract][Full Text] [Related]
8. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
[TBL] [Abstract][Full Text] [Related]
9. Human leucocyte antigen class I-redirected anti-tumour CD4
Tan MP; Dolton GM; Gerry AB; Brewer JE; Bennett AD; Pumphrey NJ; Jakobsen BK; Sewell AK
Clin Exp Immunol; 2017 Jan; 187(1):124-137. PubMed ID: 27324616
[TBL] [Abstract][Full Text] [Related]
10. Human CD8+ TCR-alpha beta(+) and TCR-gamma delta(+) cells modulate autologous autoreactive neuroantigen-specific CD4+ T-cells by different mechanisms.
Correale J; Rojany M; Weiner LP
J Neuroimmunol; 1997 Dec; 80(1-2):47-64. PubMed ID: 9413259
[TBL] [Abstract][Full Text] [Related]
11. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
[TBL] [Abstract][Full Text] [Related]
12. A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.
Bouquié R; Bonnin A; Bernardeau K; Khammari A; Dréno B; Jotereau F; Labarrière N; Lang F
Cancer Immunol Immunother; 2009 Apr; 58(4):553-66. PubMed ID: 18751701
[TBL] [Abstract][Full Text] [Related]
13. MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.
Ray S; Chhabra A; Chakraborty NG; Hegde U; Dorsky DI; Chodon T; von Euw E; Comin-Anduix B; Koya RC; Ribas A; Economou JS; Rosenberg SA; Mukherji B;
Clin Immunol; 2010 Sep; 136(3):338-47. PubMed ID: 20547105
[TBL] [Abstract][Full Text] [Related]
14. Avidity characterization of genetically engineered T-cells with novel and established approaches.
Hillerdal V; Boura VF; Björkelund H; Andersson K; Essand M
BMC Immunol; 2016 Jul; 17(1):23. PubMed ID: 27411667
[TBL] [Abstract][Full Text] [Related]
15. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
[TBL] [Abstract][Full Text] [Related]
16. Impact of antigen presentation on TCR modulation and cytokine release: implications for detection and sorting of antigen-specific CD8+ T cells using HLA-A2 wild-type or HLA-A2 mutant tetrameric complexes.
Jäger E; Salter R; Castelli C; Höhn H; Freitag K; Karbach J; Neukirch C; Necker A; Knuth A; Maeurer MJ
J Immunol; 2002 Mar; 168(6):2766-72. PubMed ID: 11884444
[TBL] [Abstract][Full Text] [Related]
17. Ex vivo IFN-gamma secretion by circulating CD8 T lymphocytes: implications of a novel approach for T cell monitoring in infectious and malignant diseases.
Pittet MJ; Zippelius A; Speiser DE; Assenmacher M; Guillaume P; Valmori D; Liénard D; Lejeune F; Cerottini JC; Romero P
J Immunol; 2001 Jun; 166(12):7634-40. PubMed ID: 11390521
[TBL] [Abstract][Full Text] [Related]
18. Lysosome-associated membrane glycoprotein 1 predicts fratricide amongst T cell receptor transgenic CD8+ T cells directed against tumor-associated antigens.
Kirschner A; Thiede M; Blaeschke F; Richter GH; Gerke JS; Baldauf MC; Grünewald TG; Busch DH; Burdach S; Thiel U
Oncotarget; 2016 Aug; 7(35):56584-56597. PubMed ID: 27447745
[TBL] [Abstract][Full Text] [Related]
19. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.
Yee C; Savage PA; Lee PP; Davis MM; Greenberg PD
J Immunol; 1999 Feb; 162(4):2227-34. PubMed ID: 9973498
[TBL] [Abstract][Full Text] [Related]
20. Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes.
Schaft N; Willemsen RA; de Vries J; Lankiewicz B; Essers BW; Gratama JW; Figdor CG; Bolhuis RL; Debets R; Adema GJ
J Immunol; 2003 Feb; 170(4):2186-94. PubMed ID: 12574392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
